Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
Back to Newsroom
Mentioned in this Article

Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer

Tuesday, May 18, 2021 8:00 AM
Share this article now
Company Update

SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small molecule drug ("SMD") for the treatment of colon cancer. SMD is defined as any organic compound that enters cells easily because it has low molecular weight (< 900 daltons). Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. This is different from drugs that have a large molecular weight, which keep them from getting inside cells easily. Their small size makes them easily ingestible in the gastrointestinal tract where active substances are immediately absorbed into the bloodstream and can travel anywhere in the body. The small size of these molecules allows them to easily penetrate cell membranes as they travel throughout the body.

SMD's have a preference, if successfully developed, over "large molecule", or biologics, in that SMD's can be generally taken orally, easier to use, more accessible, and usually do not require doctor visits at time of administration. Many targeted therapies have in the past been small molecules. In the last several years large pharma companies have been developing biologics and have chosen to acquire smaller companies that have been developing small-molecule drugs. They generally have a lower cost to the patient. The successful development of SMDs has great interest by larger pharmaceutical companies due to the widely available attributes that have a demand on a global basis.


ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.


Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.


For additional Information, please contact the Oncology Pharma at:

One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: [email protected]

SOURCE: Oncology Pharma Inc.

Oncology Pharma Inc.
Back to Newsroom


Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions